ABOUT US
TEAM
PARTNERS
CATALOGUE

Syngeneic

Models

VIEW MODELS

GEMMs

Genetically Engineered Models

VIEW MODELS

GEMMs

with Human Targets

VIEW MODELS

PDX

Patient-Derived Xenografts

VIEW MODELS

Humanised Xenograft

Models

VIEW MODELS
FACILITIES
NEWS
PUBLICATION TRACK

Publication Track

Navarra.com

Researchers at Cima University of Navarra achieve important progress against cancer.

2025 Jun

Blood Cancer Discov

Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma.

2024 May 1

NATURE MEDICINE

Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma.

2023 Mar

Nature Communications

Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance.

2023 Sep 20

Sci Adv

Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death.

2022 Jan 21

Blood

The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma.

2022 Jan 20

Blood

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.

2021 Jan 7

Blood

PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas.

2019 May 30

Blood

Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics.

2016 Jun 14

Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma.

2014 Jun 26

Downregulation of FOXP1 is required during germinal center B-cell function

C/EBPα induces highly efficient macrophage transdifferentiation of B lymphoma and leukemia cell lines and impairs their tumorigenicity.

PNAS

Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice.

2012 Jun 26

PNAS

A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma.

2011 Jul 26

Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma.

2010 Oct 7